Cardiac amyloidosis is considered a rare disease, but as diagnostic capabilities increase, so does the assessment of its prevalence. Cardiac amyloidosis manifests itself with symptoms of restrictive cardiomyopathy, leading to progressive heart failure. However, the underlying pathogenetic mechanisms of the disease differ. This literature review provides an overview of cardiac amyloidosis, from classification to molecular mechanisms and modern treatment options.
No takes yet. Share an insight, caveat, or question.
Demyanenko et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: